OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
